S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

Alteryx (AYX) Stock Forecast, Price & News

$39.55
+1.64 (+4.33%)
(As of 06/8/2023 ET)
Compare
Today's Range
$37.70
$39.63
50-Day Range
$35.48
$58.84
52-Week Range
$34.70
$70.63
Volume
1.92 million shs
Average Volume
1.53 million shs
Market Capitalization
$2.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.15

Alteryx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
86.1% Upside
$73.15 Price Target
Short Interest
Healthy
4.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.66mentions of Alteryx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$337,925 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.96) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Computer And Technology Sector

149th out of 594 stocks

Prepackaged Software Industry

32nd out of 212 stocks


AYX stock logo

About Alteryx (NYSE:AYX) Stock

Alteryx, Inc. engages in the provision of self-service data analytics software. Its subscription-based platform allows organizations to prepare, blend, and analyze data from a multitude of sources and benefit from data-driven decisions. The company was founded by Dean A. Stoecker, Olivia Duane-Adams, and Edward P. Harding, Jr. in March 1997 and is headquartered in Irvine, CA.

Receive AYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alteryx and its competitors with MarketBeat's FREE daily newsletter.

AYX Stock News Headlines

Is Alteryx Stock Presenting a Buying Opportunity?
Alteryx Inc. (NYSE: AYX) is a big data analytics automation platform enabling companies to collect, process, prepare and analyze data in different formats from
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Alteryx (NYSE:AYX) Shares Gap Up to $38.94
Bank of America Upgrades Alteryx (NYSE:AYX) to "Buy"
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Why Is Alteryx (AYX) Stock Soaring Today
Alteryx (NYSE:AYX) Trading 2.7% Higher
Alteryx: Trying To Board The AI Hype Train
The Latest Analyst Ratings for Alteryx
Alteryx, Inc. (NYSE:AYX) Short Interest Down 17.5% in April
See More Headlines

AYX Price History

AYX Company Calendar

Last Earnings
4/27/2023
Today
6/08/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
2,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$73.15
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+85.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-318,500,000.00
Pretax Margin
-33.03%

Debt

Sales & Book Value

Annual Sales
$855.35 million
Book Value
$2.50 per share

Miscellaneous

Free Float
60,897,000
Market Cap
$2.78 billion
Optionable
Optionable
Beta
0.50

Key Executives

  • Mark F. Anderson
    Chief Executive Officer & Director
  • Paula Hansen
    President & Chief Revenue Officer
  • Kevin RubinKevin Rubin
    Chief Financial Officer
  • Digvijay Lamba
    Chief Technology Officer
  • Trevor Schulze
    Chief Information Officer













AYX Stock - Frequently Asked Questions

Should I buy or sell Alteryx stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alteryx in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYX shares.
View AYX analyst ratings
or view top-rated stocks.

What is Alteryx's stock price forecast for 2023?

12 Wall Street analysts have issued twelve-month price targets for Alteryx's stock. Their AYX share price forecasts range from $50.00 to $95.00. On average, they expect the company's share price to reach $73.15 in the next twelve months. This suggests a possible upside of 85.1% from the stock's current price.
View analysts price targets for AYX
or view top-rated stocks among Wall Street analysts.

How have AYX shares performed in 2023?

Alteryx's stock was trading at $50.67 at the beginning of the year. Since then, AYX shares have decreased by 22.0% and is now trading at $39.53.
View the best growth stocks for 2023 here
.

Are investors shorting Alteryx?

Alteryx saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,290,000 shares, an increase of 10.4% from the April 30th total of 2,980,000 shares. Based on an average trading volume of 1,500,000 shares, the short-interest ratio is presently 2.2 days.
View Alteryx's Short Interest
.

When is Alteryx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our AYX earnings forecast
.

How were Alteryx's earnings last quarter?

Alteryx, Inc. (NYSE:AYX) issued its quarterly earnings data on Thursday, April, 27th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.31. The business had revenue of $199.09 million for the quarter, compared to analyst estimates of $199.81 million. Alteryx had a negative net margin of 33.68% and a negative trailing twelve-month return on equity of 139.14%.

What guidance has Alteryx issued on next quarter's earnings?

Alteryx issued an update on its second quarter 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of -$0.69--$0.65 for the period, compared to the consensus estimate of -$0.42. The company issued revenue guidance of $180.00 million-$184.00 million, compared to the consensus revenue estimate of $205.10 million.

What is Mark Anderson's approval rating as Alteryx's CEO?

8 employees have rated Alteryx Chief Executive Officer Mark Anderson on Glassdoor.com. Mark Anderson has an approval rating of 99% among the company's employees. This puts Mark Anderson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alteryx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alteryx investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Salesforce (CRM), Shopify (SHOP), Alibaba Group (BABA), Twilio (TWLO), PayPal (PYPL), Okta (OKTA) and Tesla (TSLA).

When did Alteryx IPO?

(AYX) raised $117 million in an IPO on Friday, March 24th 2017. The company issued 9,000,000 shares at $12.00-$14.00 per share. Goldman, Sachs, J.P. Morgan, Barclays and Citigroup served as the underwriters for the IPO and Pacifc iCrest Securities (a division of KeyBanc Capital Markets), William Blair, JMP Securities, Raymond James and Cowen and Company were co-managers.

What is Alteryx's stock symbol?

Alteryx trades on the New York Stock Exchange (NYSE) under the ticker symbol "AYX."

Who are Alteryx's major shareholders?

Alteryx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.00%), Mackenzie Financial Corp (3.73%), Bares Capital Management Inc. (3.03%), Assenagon Asset Management S.A. (2.11%), Federated Hermes Inc. (1.47%) and Brown Capital Management LLC (1.20%). Insiders that own company stock include Charles Cory, Chris Natali, Christopher M Lal, Dean Stoecker, Derek Knudsen, Eileen Schloss, Jeff Horing, Kevin Rubin, Paula Hansen, Reuters Corp /Can/ Thomson, Robert Scott Jones, Scott Davidson, Timothy I Maudlin and Timothy I Maudlin.
View institutional ownership trends
.

How do I buy shares of Alteryx?

Shares of AYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alteryx's stock price today?

One share of AYX stock can currently be purchased for approximately $39.53.

How much money does Alteryx make?

Alteryx (NYSE:AYX) has a market capitalization of $2.78 billion and generates $855.35 million in revenue each year. The company earns $-318,500,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis.

How many employees does Alteryx have?

The company employs 2,900 workers across the globe.

How can I contact Alteryx?

Alteryx's mailing address is 3345 Michelson Drive Suite 400, Irvine CA, 92612. The official website for the company is www.alteryx.com. The company can be reached via phone at (888) 836-4274 or via email at ir@alteryx.com.

This page (NYSE:AYX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -